| 1800 | Humans |
| 1800 | COVID-19 |
| 1463 | SARS-CoV-2 |
| 1371 | Hydroxychloroquine |
| 1138 | Pandemics |
| 1029 | Coronavirus Infections |
| 1015 | Pneumonia, Viral |
| 890 | Betacoronavirus |
| 722 | Antiviral Agents |
| 615 | Male |
| 601 | Female |
| 479 | Middle Aged |
| 406 | Aged |
| 379 | Azithromycin |
| 353 | Adult |
| 330 | Chloroquine |
| 321 | Treatment Outcome |
| 211 | Antimalarials |
| 191 | Retrospective Studies |
| 187 | Ritonavir |
| 187 | Lopinavir |
| 185 | Drug Therapy, Combination |
| 152 | Drug Combinations |
| 149 | Aged, 80 and over |
| 143 | Hospitalization |
| 137 | Anti-Bacterial Agents |
| 136 | Alanine |
| 136 | Adenosine Monophosphate |
| 133 | Antibodies, Monoclonal, Humanized |
| 129 | Drug Repositioning |
| 126 | Clinical Trials as Topic |
| 122 | Severity of Illness Index |
| 118 | Risk Factors |
| 103 | Randomized Controlled Trials as Topic |
| 99 | Young Adult |
| 96 | Antirheumatic Agents |
| 93 | Comorbidity |
| 91 | Long QT Syndrome |
| 84 | Adolescent |
| 83 | Respiration, Artificial |
| 83 | Animals |
| 79 | United States |
| 79 | Electrocardiography |
| 75 | Intensive Care Units |
| 74 | Tomography, X-Ray Computed |
| 70 | Immunization, Passive |
| 70 | COVID-19 Testing |
| 69 | Immunosuppressive Agents |
| 69 | Enzyme Inhibitors |
| 67 | Child |
| 63 | Risk Assessment |
| 62 | Italy |
| 61 | Time Factors |
| 61 | Lung |
| 59 | Immunologic Factors |
| 56 | Adrenal Cortex Hormones |
| 55 | Glucocorticoids |
| 53 | Clinical Laboratory Techniques |
| 52 | Prognosis |
| 51 | Anti-Inflammatory Agents |
| 50 | Pyrazines |
| 50 | Amides |
| 49 | Anticoagulants |
| 49 | Angiotensin-Converting Enzyme 2 |
| 48 | Cytokine Release Syndrome |
| 47 | Spain |
| 46 | Viral Load |
| 46 | Prospective Studies |
| 46 | Length of Stay |
| 46 | Arrhythmias, Cardiac |
| 45 | Hospital Mortality |
| 44 | Incidence |
| 43 | Rheumatic Diseases |
| 43 | Drug Interactions |
| 41 | Anti-Infective Agents |
| 40 | Transplant Recipients |
| 40 | China |
| 39 | Respiratory Distress Syndrome |
| 39 | Lupus Erythematosus, Systemic |
| 39 | COVID-19 Vaccines |
| 38 | Molecular Docking Simulation |
| 37 | Cohort Studies |
| 37 | Child, Preschool |
| 36 | India |
| 36 | Cardiovascular Diseases |
| 36 | Age Factors |
| 35 | RNA, Viral |
| 35 | Pregnancy |
| 35 | Kidney Transplantation |
| 35 | Immunoglobulins, Intravenous |
| 35 | Immunocompromised Host |
| 35 | Disease Progression |
| 34 | Peptidyl-Dipeptidase A |
| 34 | Critical Illness |
| 33 | Oxygen Inhalation Therapy |
| 32 | Spike Glycoprotein, Coronavirus |
| 32 | Oseltamivir |
| 32 | Infant |
| 32 | Drug Administration Schedule |
| 32 | Cytokines |
| 31 | Virus Replication |
| 31 | Coronavirus |
| 30 | France |
| 30 | Follow-Up Studies |
| 30 | Fever |
| 30 | Cross-Sectional Studies |
| 30 | Angiotensin-Converting Enzyme Inhibitors |
| 29 | Practice Guidelines as Topic |
| 29 | Dexamethasone |
| 28 | Pregnancy Complications, Infectious |
| 28 | Evidence-Based Medicine |
| 28 | Arthritis, Rheumatoid |
| 27 | Methylprednisolone |
| 27 | Interleukin-6 |
| 27 | Host-Pathogen Interactions |
| 27 | C-Reactive Protein |
| 26 | Torsades de Pointes |
| 25 | Surveys and Questionnaires |
| 25 | Neoplasms |
| 25 | Hypertension |
| 25 | Dose-Response Relationship, Drug |
| 25 | Critical Care |
| 24 | Survival Analysis |
| 24 | Research Design |
| 24 | Pre-Exposure Prophylaxis |
| 24 | Kidney Failure, Chronic |
| 24 | Infant, Newborn |
| 24 | Graft Rejection |
| 24 | Double-Blind Method |
| 23 | Viral Vaccines |
| 23 | Inflammation |
| 23 | Immunosuppression |
| 23 | Health Personnel |
| 23 | Fatal Outcome |
| 22 | Off-Label Use |
| 22 | Drug Monitoring |
| 22 | Combined Modality Therapy |
| 22 | COVID-19 Nucleic Acid Testing |
| 21 | Reverse Transcriptase Polymerase Chain Reaction |
| 21 | Drug Synergism |
| 21 | Cough |
| 21 | Case-Control Studies |
| 20 | Ivermectin |
| 20 | Diabetes Mellitus |
| 20 | Biomarkers |
| 20 | Acute Kidney Injury |
| 19 | Registries |
| 19 | Patient Safety |
| 19 | New York City |
| 19 | Hypoxia |
| 19 | Cardiotoxicity |
| 18 | Respiratory Insufficiency |
| 18 | Protease Inhibitors |
| 18 | Immunomodulation |
| 18 | Heart Diseases |
| 18 | Chemoprevention |
| 17 | Virus Internalization |
| 17 | Sex Factors |
| 17 | Ribavirin |
| 17 | Renal Dialysis |
| 17 | Nasopharynx |
| 17 | Molecular Dynamics Simulation |
| 17 | Intubation, Intratracheal |
| 17 | Indoles |
| 17 | Extracorporeal Membrane Oxygenation |
| 17 | Dyspnea |
| 17 | Coronavirus 3C Proteases |
| 16 | Vero Cells |
| 16 | United States Food and Drug Administration |
| 16 | Uncertainty |
| 16 | Thrombosis |
| 16 | Telemedicine |
| 16 | Symptom Assessment |
| 16 | Severe Acute Respiratory Syndrome |
| 16 | Practice Patterns, Physicians' |
| 16 | Post-Exposure Prophylaxis |
| 16 | Janus Kinase Inhibitors |
| 16 | Interferons |
| 16 | Global Health |
| 16 | Disease Management |
| 16 | Computer Simulation |
| 16 | Chlorocebus aethiops |
| 15 | Treatment Failure |
| 15 | Survival Rate |
| 15 | Receptors, Interleukin-6 |
| 15 | Patient Selection |
| 15 | Outpatients |
| 15 | Observational Studies as Topic |
| 15 | Mortality |
| 15 | Enoxaparin |
| 15 | Drug Discovery |
| 15 | Darunavir |
| 15 | Coinfection |
| 15 | Ceftriaxone |
| 14 | Oxygen |
| 14 | Obesity |
| 14 | Lysosomes |
| 14 | Iran |
| 14 | Glucosephosphate Dehydrogenase Deficiency |
| 14 | Fibrin Fibrinogen Degradation Products |
| 14 | Drug-Related Side Effects and Adverse Reactions |
| 14 | Disease Outbreaks |
| 14 | Diagnosis, Differential |
| 14 | Binding Sites |
| 14 | Autoimmune Diseases |
| 14 | Angiotensin Receptor Antagonists |
| 14 | Ambulatory Care |
| 13 | Viral Nonstructural Proteins |
| 13 | Signal Transduction |
| 13 | SARS Virus |
| 13 | Proportional Hazards Models |
| 13 | Prednisone |
| 13 | Personal Protective Equipment |
| 13 | Malaria |
| 13 | Infection Control |
| 13 | Heart Failure |
| 13 | Drug Evaluation, Preclinical |
| 13 | Databases, Factual |
| 13 | Brazil |
| 13 | Antibodies, Monoclonal |
| 13 | Anti-Inflammatory Agents, Non-Steroidal |
| 13 | Administration, Oral |
| 12 | World Health Organization |
| 12 | Sulfonamides |
| 12 | Rheumatologists |
| 12 | Pharmacovigilance |
| 12 | Models, Biological |
| 12 | Liver Transplantation |
| 12 | Interleukin 1 Receptor Antagonist Protein |
| 12 | Inpatients |
| 12 | Heparin, Low-Molecular-Weight |
| 12 | HIV Infections |
| 12 | Drug Approval |
| 12 | Delivery of Health Care |
| 12 | Azetidines |
| 12 | Ascorbic Acid |
| 11 | Steroids |
| 11 | Standard of Care |
| 11 | Retinal Diseases |
| 11 | Real-Time Polymerase Chain Reaction |
| 11 | Public Health |
| 11 | Protein Binding |
| 11 | Prevalence |
| 11 | Outcome and Process Assessment, Health Care |
| 11 | Outcome Assessment, Health Care |
| 11 | Organ Transplantation |
| 11 | Myocarditis |
| 11 | Multicenter Studies as Topic |
| 11 | Lymphopenia |
| 11 | Logistic Models |
| 11 | Interferon beta-1a |
| 11 | Drug Development |
| 11 | Disease Models, Animal |
| 11 | Deprescriptions |
| 11 | Cysteine Endopeptidases |
| 10 | Serine Endopeptidases |
| 10 | Rheumatology |
| 10 | Republic of Korea |
| 10 | Renal Insufficiency, Chronic |
| 10 | Odds Ratio |
| 10 | Noninvasive Ventilation |
| 10 | Mice |
| 10 | Kaplan-Meier Estimate |
| 10 | Interferon beta-1b |
| 10 | Hospitals |
| 10 | Compassionate Use Trials |
| 10 | Autophagy |
| 10 | Antineoplastic Agents |
| 10 | Antibodies, Viral |
| 10 | Acute Generalized Exanthematous Pustulosis |
| 9 | Virus Shedding |
| 9 | Turkey |
| 9 | Risk |
| 9 | Radiography, Thoracic |
| 9 | Politics |
| 9 | Pharmaceutical Preparations |
| 9 | Multiple Organ Failure |
| 9 | Molecular Targeted Therapy |
| 9 | Lung Neoplasms |
| 9 | Immunotherapy |
| 9 | Hypoglycemic Agents |
| 9 | Heparin |
| 9 | Hemolysis |
| 9 | Ferritins |
| 9 | Emergency Service, Hospital |
| 9 | Diabetes Complications |
| 9 | Communicable Disease Control |
| 9 | Colchicine |
| 9 | Biological Products |
| 8 | Tumor Necrosis Factor Inhibitors |
| 8 | Teicoplanin |
| 8 | Social Media |
| 8 | Protective Factors |
| 8 | Postoperative Complications |
| 8 | Mycophenolic Acid |
| 8 | Models, Molecular |
| 8 | Mental Disorders |
| 8 | Information Dissemination |
| 8 | Infectious Disease Transmission, Patient-to-Professional |
| 8 | Immunity, Innate |
| 8 | Heart Transplantation |
| 8 | Health Services Accessibility |
| 8 | Endosomes |
| 8 | Drug Eruptions |
| 8 | Diarrhea |
| 8 | Diabetes Mellitus, Type 2 |
| 8 | Clinical Decision-Making |
| 8 | Antibodies, Neutralizing |
| 8 | Adverse Drug Reaction Reporting Systems |
| 7 | Zinc |
| 7 | Thiazoles |
| 7 | Tacrolimus |
| 7 | T-Lymphocytes |
| 7 | Systemic Inflammatory Response Syndrome |
| 7 | Spondylarthropathies |
| 7 | Societies, Medical |
| 7 | Skin |
| 7 | Skin Diseases |
| 7 | Receptors, Virus |
| 7 | Quarantine |
| 7 | Pulmonary Disease, Chronic Obstructive |
| 7 | Protein Kinase Inhibitors |
| 7 | Premature Birth |
| 7 | Prednisolone |
| 7 | Polymerase Chain Reaction |
| 7 | Pneumonia |
| 7 | Patient Admission |
| 7 | Occupational Exposure |
| 7 | New York |
| 7 | Multivariate Analysis |
| 7 | Models, Theoretical |
| 7 | Medicine, Chinese Traditional |
| 7 | Mass Media |
| 7 | Macrolides |
| 7 | Lung Diseases, Interstitial |
| 7 | Interferon Type I |
| 7 | Hydrogen-Ion Concentration |
| 7 | Host Microbial Interactions |
| 7 | Heart Rate |
| 7 | Fatigue |
| 7 | Europe |
| 7 | Erythrocyte Transfusion |
| 7 | Echocardiography |
| 7 | Drugs, Investigational |
| 7 | Drug Utilization |
| 7 | Drug Prescriptions |
| 7 | Drug Overdose |
| 7 | Drug Industry |
| 7 | Disease Transmission, Infectious |
| 7 | Disease Susceptibility |
| 7 | Cytochrome P-450 CYP3A Inhibitors |
| 7 | Cross Infection |
| 7 | Communication |
| 7 | Chromatography, High Pressure Liquid |
| 7 | Cesarean Section |
| 7 | Cause of Death |
| 6 | Vitamins |
| 6 | Time-to-Treatment |
| 6 | Thrombophilia |
| 6 | Safety |
| 6 | Rituximab |
| 6 | Risk Adjustment |
| 6 | Retina |
| 6 | Renin-Angiotensin System |
| 6 | Renal Replacement Therapy |
| 6 | Renal Insufficiency |
| 6 | Pyrazoles |
| 6 | Plasmapheresis |
| 6 | Pilot Projects |
| 6 | Ophthalmology |
| 6 | Middle East Respiratory Syndrome Coronavirus |
| 6 | Methotrexate |
| 6 | Magnetic Resonance Imaging |
| 6 | Lymphohistiocytosis, Hemophagocytic |
| 6 | Ligands |
| 6 | Interferon-alpha |
| 6 | Immunoglobulins |
| 6 | Hydroxymethylglutaryl-CoA Reductase Inhibitors |
| 6 | Hospitals, University |
| 6 | HIV Protease Inhibitors |
| 6 | Exanthema |
| 6 | Emergencies |
| 6 | Drug Delivery Systems |
| 6 | Doxycycline |
| 6 | Death, Sudden, Cardiac |
| 6 | Contraindications, Drug |
| 6 | Cobicistat |
| 6 | Chronic Disease |
| 6 | Cell Line |
| 6 | Biomedical Research |
| 6 | Bias |
| 6 | Anxiety |
| 6 | Antioxidants |
| 6 | Anticonvulsants |
| 6 | Aging |
| 6 | Administration, Inhalation |
| 5 | Urticaria |
| 5 | United Kingdom |
| 5 | Tumor Necrosis Factor-alpha |
| 5 | Thermodynamics |
| 5 | Therapies, Investigational |
| 5 | Tertiary Care Centers |
| 5 | Superinfection |
| 5 | Social Isolation |
| 5 | Shock, Septic |
| 5 | Sample Size |
| 5 | Reproducibility of Results |
| 5 | Recurrence |
| 5 | Radiography |
| 5 | Psychotropic Drugs |
| 5 | Psoriasis |
| 5 | Protein Interaction Domains and Motifs |
| 5 | Protein Domains |
| 5 | Propensity Score |
| 5 | Potassium |
| 5 | Polypharmacy |
| 5 | Placebos |
| 5 | Physicians |
| 5 | Physical Distancing |
| 5 | Periodicals as Topic |
| 5 | Patient Discharge |
| 5 | Oxidative Stress |
| 5 | Occupational Health |
| 5 | Netherlands |
| 5 | Monitoring, Physiologic |
| 5 | Molecular Structure |
| 5 | Meta-Analysis as Topic |
| 5 | Mesenchymal Stem Cell Transplantation |
| 5 | Liver |
| 5 | Liver Function Tests |
| 5 | L-Lactate Dehydrogenase |
| 5 | Kinetics |
| 5 | Internet |
| 5 | Interleukin-1 |
| 5 | Influenza, Human |
| 5 | Infectious Disease Transmission, Vertical |
| 5 | Heart |
| 5 | Heart Conduction System |
| 5 | Gestational Age |
| 5 | Genetic Predisposition to Disease |
| 5 | Gastrointestinal Diseases |
| 5 | Endpoint Determination |
| 5 | Endocytosis |
| 5 | Drug Dosage Calculations |
| 5 | Developing Countries |
| 5 | Databases, Pharmaceutical |
| 5 | Convalescence |
| 5 | Clinical Protocols |
| 5 | Chemical and Drug Induced Liver Injury |
| 5 | Cardiomyopathies |
| 5 | Canada |
| 5 | Body Mass Index |
| 5 | Blood Glucose |
| 5 | Asymptomatic Infections |
| 5 | Asymptomatic Diseases |
| 5 | Arthritis, Psoriatic |
| 5 | Antihypertensive Agents |
| 5 | Anti-Retroviral Agents |
| 5 | Aminoquinolines |
| 5 | Amino Acid Sequence |
| 5 | Algorithms |
| 5 | Acute Disease |
| 4 | Withholding Treatment |
| 4 | Vitamin D |
| 4 | Virus Attachment |
| 4 | Virulence |
| 4 | Thromboembolism |
| 4 | Thrombocytopenia |
| 4 | Tachycardia, Ventricular |
| 4 | Stereoisomerism |
| 4 | Statistics as Topic |
| 4 | Specimen Handling |
| 4 | Smoking |
| 4 | Single-Blind Method |
| 4 | Sex Distribution |
| 4 | Seizures |
| 4 | Saudi Arabia |
| 4 | Research |
| 4 | Referral and Consultation |
| 4 | Reactive Oxygen Species |
| 4 | Rats |
| 4 | Purines |
| 4 | Pulmonary Embolism |
| 4 | Publication Bias |
| 4 | Psychoses, Substance-Induced |
| 4 | Programmed Cell Death 1 Receptor |
| 4 | Pregnancy Outcome |
| 4 | Predictive Value of Tests |
| 4 | Plasma |
| 4 | Pharmacogenetics |
| 4 | Peru |
| 4 | Pediatrics |
| 4 | Patient Acuity |
| 4 | Palliative Care |
| 4 | Ototoxicity |
| 4 | Obesity, Maternal |
| 4 | Nursing Homes |
| 4 | Nausea |
| 4 | Myalgia |
| 4 | Lymphocyte Count |
